Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Oct 30, 2026
TickeronGET DAILY SIGNALS
Henry Schein (HSIC) vs NiSource (NI): Distribution Momentum Meets Utility Stability

Henry Schein (HSIC) vs NiSource (NI): Distribution Momentum Meets Utility Stability

Key Takeaways

  • Henry Schein (HSIC) is a global distributor of dental and medical supplies, while NiSource (NI) is a regulated natural gas and electric utility — two fundamentally different business models, growth drivers, and risk profiles.
  • HSIC has shown stronger relative price momentum over the past year, while NI has lagged the broader market despite a compelling long-term data center growth story.
  • HSIC carries a broad "Buy" analyst consensus with meaningful upside to average price targets, whereas NI's outlook hinges on execution of a $40 billion capital plan and regulatory approvals.
  • Tickeron AI Verdict: HSIC — based on stronger trend consistency, improving earnings momentum, and more favorable near-term positioning relative to NI.
  • For deeper insight, explore HSIC Major News and HSIC Today's Price Move, as well as NI Major News and NI Today's Price Move.
  • Interested in automated, data-driven signals? Discover the Trending AI Robots curated by Tickeron for current market conditions.

Setting the Stage

This stock comparison examines two companies that rarely appear side by side: HSIC, the world's largest provider of healthcare solutions to office-based dental and medical practitioners, and NI, a regulated utility serving roughly four million natural gas and electric customers across six states. They occupy different sectors — healthcare distribution versus utilities — yet both are mid-to-large-cap names facing meaningful catalysts. Traders evaluating relative momentum and investors weighing growth against stability may find this comparison useful. Understanding how each company is positioned across business model, momentum, and risk can clarify which profile better fits current market conditions. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.

HSIC Overview and Recent Performance

Henry Schein, Inc. (HSIC) distributes dental and medical products, equipment, technology, and value-added services to practitioners worldwide. Recent market activity reflects renewed optimism around the company's execution. In recent quarters, the firm reported sales growth of roughly 6.7% and raised its full-year sales growth guidance to a range of 4.5% to 5.5%, supported by stable dental demand and market-share gains. Management has outlined a program targeting at least $200 million in operating income improvement, alongside a leaner cost structure. A leadership transition, including a new chief financial officer, and new technology distribution partnerships have added to the narrative. Shares have advanced roughly 15% year to date, with a one-year total return near 36%, and most analysts maintain a "Buy" rating with an average price target above the prevailing price.

NI Overview and Recent Performance

NiSource Inc. (NI) operates regulated natural gas and electric utilities, including NIPSCO in Indiana and Columbia Gas across several states. Recent performance has been steady but comparatively muted: shares have added only about 4% year to date, underperforming the broader market. The company's third-quarter report showed adjusted earnings per share of $0.27, beating consensus, though revenue fell slightly short of estimates. NI has extended its capital plan through 2033 to roughly $40 billion and raised its long-term adjusted earnings growth outlook, anchored by a fast-growing GenCo (generation company) segment serving data centers. A 20-year electricity agreement with Microsoft, alongside deals with Amazon and Alphabet, underpins this strategy. Offsetting tailwinds are elevated financing needs, planned equity issuance, and cost pressures from a severe August storm in Indiana. From what I see, the data center angle is worth monitoring closely over the longer term.

Head-to-Head Comparison

The core contrast between these two stocks is cyclical growth versus regulated stability. HSIC is a healthcare distribution business with a lower beta (about 0.84), cyclical exposure to dental and medical procedure volumes, and a restructuring-driven margin story. Its growth is tied to organic volume, private-label penetration, and disciplined acquisition activity. NI, by contrast, is a capital-intensive utility offering a forward dividend yield near 2.7% and earnings visibility from regulated rate recovery, but it faces financing risk from its expanded capital plan and dilution from planned equity issuance. On momentum, HSIC has clearly outperformed over the past year, while NI's data center pipeline represents a longer-dated catalyst that may take years to fully contribute. Risk profiles differ sharply: HSIC carries execution and demand-cycle risk, whereas NI carries regulatory, weather, and balance-sheet leverage risk. I’m watching this closely as the relative performance gap continues to widen.

Tickeron AI Verdict

Based on observable factors — including trend consistency, relative performance, analyst sentiment, and the timing of catalysts — Tickeron's AI would likely favor HSIC over NI in the current environment. HSIC's stronger year-to-date and one-year returns, improving earnings trajectory, and broad "Buy" consensus point to more favorable near-term positioning and trend quality. NI's long-term data center growth story is compelling but is largely back-end loaded and carries financing and regulatory execution uncertainty. As always, this is a probabilistic assessment of current conditions rather than a guarantee of future outcomes.

Using Tickeron’s AI Trading Bots for Deeper Analysis

In my view, incorporating systematic tools can add useful perspective when comparing names like these. Tickeron’s AI Trading Bots allow users to review a range of algorithmic strategies, each with its own performance history and ticker focus, helping align automated signals with individual risk preferences and time horizons.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HSIC, NI

HSIC in downward trend: price dove below 50-day moving average on November 19, 2026

HSIC moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend. In 24 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HSIC as a result. In 65 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

The Moving Average Convergence Divergence Histogram (MACD) for HSIC turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 29 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

HSIC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 55 cases where HSIC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

The 10-day moving average for HSIC crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.

Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSIC advanced for three days, in 160 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

The Aroon Indicator entered an Uptrend today. In 136 of 252 cases where HSIC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HSIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.038) is normal, around the industry mean (14.423). P/E Ratio (24.870) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (1.715) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.750) is also within normal values, averaging (4.260).

The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 23.75B. The market cap for tickers in the group ranges from 44.8K to 123.68B. MCK holds the highest valuation in this group at 123.68B. The lowest valued company is COCM at 44.8K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -3%. For the same Industry, the average monthly price growth was -23%, and the average quarterly price growth was -27%. MEDS experienced the highest price growth at 80%, while ACH experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 325%. For the same stocks of the Industry, the average monthly volume growth was 539% and the average quarterly volume growth was 207%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 48
Price Growth Rating: 61
SMR Rating: 88
Profit Risk Rating: 73
Seasonality Score: 3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a distributer of healthcare products and services

Industry MedicalDistributors

Industry
Medical Distributors
Address
135 Duryea Road
Phone
+1 631 843-5500
Employees
25000
Web
https://www.henryschein.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.